Oxford BioMedica plc (OXB) Insider Acquires £2,671.65 in Stock
Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo bought 29,685 shares of the stock in a transaction dated Friday, September 22nd. The stock was purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,602.06).
Shares of Oxford BioMedica plc (OXB) opened at 8.75 on Monday. The firm’s market capitalization is GBX 270.22 million. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 11.25. The company’s 50 day moving average price is GBX 8.85 and its 200-day moving average price is GBX 6.66.
TRADEMARK VIOLATION NOTICE: “Oxford BioMedica plc (OXB) Insider Acquires £2,671.65 in Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/25/oxford-biomedica-plc-oxb-insider-acquires-2671-65-in-stock.html.
OXB has been the subject of several research reports. Jefferies Group LLC reissued a “buy” rating and issued a GBX 13 ($0.18) target price on shares of Oxford BioMedica plc in a research note on Thursday, July 13th. N+1 Singer reissued a “hold” rating and issued a GBX 7.80 ($0.11) target price on shares of Oxford BioMedica plc in a research note on Thursday, July 6th. Shore Capital reissued a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th. Finally, Peel Hunt initiated coverage on Oxford BioMedica plc in a research note on Tuesday, September 19th. They issued a “buy” rating and a GBX 13 ($0.18) target price for the company.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.